# Alcidion Group Limited (ABN 77 143 142 410)

# Appendix 4D
# & Financial statements for the period ended 31 December 2024

## Results for announcement to the market

## Reporting Periods

| Current reporting period | Half-year ended 31 December 2024 |
|---|---|
| Previous reporting period | Half-year ended 31 December 2023 |

## Key information

| | | % Change | | $000 |
|---|---|---|---|---|
| Total revenue from ordinary activities | Down | 7.46% | to | 17,638 |
| Loss from ordinary activities after tax attributable to members | Down | 79.50% | to | (889) |
| Net loss for the period attributable to members | Down | 79.50% | to | (889) |

## Details relating to dividends

No dividends were paid or proposed for the current or previous corresponding half-year period.

## Explanation of results

First half revenue at $17,638k was 7.46% lower than prior corresponding period (PCP), this was expected given the known reduction in non-recurring product implementation due to the nearing completion of Alcidion's project implementation work for the Leidos Australia contract.

The business saw a material improvement in the net loss for the period. Net loss for the period was $889K, a decrease of $3,447k from the PCP net loss of $4,336k. The improvement in the net loss position is primarily a result of the restructure undertaken in FY24 H2, which has resulted in a decrease in employee benefits expense of $3,352K.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' report and the consolidated financial statements for the half-year ended 31 December 2024 lodged with this document.

## Net tangible assets per security

| | 31 December 2024 | 30 June 2024 |
|---|---|---|
| Net tangible assets per security | ($0.0057) | ($0.0052) |

This Appendix 4D is based on the attached half-year financial report which has been reviewed by the Group's auditors, William Buck. A copy of William Buck's review report is included in the attached half-year financial report.

For personal use only

For personal use only

# Alcidion Group Limited

## Financial report for the half year ended 31 December 2024

# CONTENTS

Directors' Report ..... 1
Auditor's Independence Declaration ..... 5
Consolidated Statement of Profit or Loss and Other Comprehensive Income ..... 6
Consolidated Statement of Financial Position ..... 7
Consolidated Statement of Changes in Equity ..... 8
Consolidated Statement of Cash Flows ..... 9
Notes to the Financial Statements ..... 10
Directors' Declaration ..... 15
Independent Auditor's Review Report ..... 16
Corporate Directory ..... 18

For personal use only

For personal use only

# Directors' Report

The directors submit herewith the financial report of Alcidion Group Limited and its subsidiaries ("Alcidion", "the Group" or, the "Company") for the half-year ended 31 December 2024. In order to comply with the provisions of the *Corporations Act 2001*, the directors report as follows:

## Directors

The following persons were directors of Alcidion Group Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

| | |
|---|---|
| Ms Rebecca Wilson | Ms Kate Quirke |
| Ms Victoria Weekes | Mr Will Smart (appointed 01 October 2024) |
| Mr Daniel Sharp | Mr Simon Chamberlain (resigned 20 October 2024) |

## Principal activities

The principal activities of Alcidion include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and Patient Administration System (PAS)), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in Australia, New Zealand and the United Kingdom.

## Review of operations

### Operating results

For the half-year period ended 31 December 2024, Alcidion delivered:

- Revenue of $17,638K a 7.5% decrease on the prior corresponding period (PCP) revenue of $19,059K
- Gross profit of $15,366K (87%) an 8.1% decrease on the PCP gross profit of $16,737K (88%)
- A loss after income tax of $889K a $3,447K (79.5%) improvement on the PCP loss of $4,336K
- An underlying EBITDA profit of $541K, a $3,329K improvement on the PCP underlying EBITDA loss of $2,788K

**Reconciliation of Loss after tax to non-IFRS EBITDA & underlying EBITDA:**

| **Half-year ended:** | **31 Dec 2024 $000** | **31 Dec 2023 $000** |
|---|---|---|
| **(Loss) after tax attributable to the owners of the company** | **(889)** | **(4,336)** |
| *Add:* | | |
| Depreciation & amortisation expense | 1,453 | 1,632 |
| Finance costs | 40 | 52 |
| *Less:* | | |
| Income tax expense benefit | 218 | 242 |
| Interest income | 57 | 30 |
| **EBITDA profit / (loss)** | **329** | **(2,924)** |
| *Add back:* | | |
| Restructure costs | 116 | - |
| Non-cash cost of performance rights | 96 | 136 |
| **Underlying EBITDA profit / (loss)** | **541** | **(2,788)** |

For personal use only

## Financial Position

**Summary of financial position:**

| | 31 Dec 2024 $000 | 30 June 2024 $000 |
|---|---|---|
| Cash and cash equivalents | 7,681 | 11,798 |
| Net current assets | (1,404) | (667) |
| Net assets/equity | 85,338 | 86,940 |
| Net tangible assets | (7,715) | (7,011) |

## Equity

**Summary of share capital:**

| | 31 Dec 2024 | 30 June 2024 |
|---|---|---|
| Issued capital ($000) | 115,515 | 115,515 |
| No. of issued shares | 1,342,952,696 | 1,342,473,221 |
| No. performance rights | 25,319,212 | 15,702,667 |
| Share price ($) | 0.060 | 0.048 |
| Market capitalisation ($M) | 80.6 | 64.4 |

## Significant contract wins and renewals

During the first half of the financial year, Alcidion contracted new sales and renewals with a total contract value (TCV) of $18.3M, with around $6.5M of that expected to be recognised in FY25.

Significant new sales signed in the period include:

**Hume Rural Health Alliance (HRHA)**

In July 2024 Alcidion announced that it had signed an agreement with HRHA for the use of Miya Precision as an enterprise digital platform with a focus on patient flow and virtual care.

The TCV of this agreement is approximately $4.0M over a 5-year period with the majority to be recognised as annual subscription revenue.

**North Adelaide Health Local Network (NAHLN)**

In November 2024 Alcidion announced that it had signed an agreement with NALHN, a portfolio of the South Australian Department for Health and Wellbeing, for use of its Miya Precision and mobile clinical task management solutions.

The deployment of Miya Precision supports real-time patient flow management; command centre operations; secure clinical task management and messaging; and mobile access to real-time data.

The TCV is $4.5M over a five-year period, structured as an initial two-year commitment with rights to extend out to five years.

**Peninsula Health**

In November 2024 Alcidion announced that it had signed an agreement with Peninsula Health for use of its Miya Precision platform.

This technology supports real-time patient flow management; command centre operations; results management; and mobile access to consolidated patient records.

The TCV is $3.7M and is structured over a total term of five years.

For personal use only

A further $6.1M of new TCV sales and renewals were made in the first half. These include an extension of our ongoing relationship with Sydney LHD, which utilises Alcidion's Miya Precision virtual care and remote patient monitoring offering and a two-year renewal for our PCS PAS module with Northumbria NHS Foundation Trust.

## Likely Developments and Expected Results

Subsequent to the period end Alcidion announced that it had signed material new contracts with Hywel Dda University Health Board and North Cumbria Integrated Care NHS Foundation Trust, details of these new contracts are summarised below:

**Hywel Dda University Health Board Wales**

On 11 February 2025, Alcidion announced that it had signed a contract with Hywel Dda University Health Board in Wales for the provision of its Miya Precision Platform – inclusive of Miya Precision for Patient Flow, Observations and Assessments and Smartpage for clinical communications and tasking. It is the first contract that Alcidion has signed in Wales.

This technology supports streamlined patient journeys, optimised clinical resource allocation, and clearer insights into patient vital signs.

The Total Contract Value (TCV) is $5.5M over a term of five years, with an option to extend to seven years, increasing the TCV to $7.7M. The agreement is structured as an annually recurring subscription licence.

**North Cumbria Integrated Care NHS Foundation Trust (NCIC)**

On 21 February 2025, Alcidion announced that it had signed a long-term contract with North Cumbria Integrated Care NHS Foundation Trust (NCIC) for use of its Miya Precision platform to provide an Electronic Patient Record (EPR).

The Total Contract Value (TCV) is $37.5M over a term of ten years with options to extend beyond that. Deployment is expected to begin immediately, with $8.0M-$9.0M of revenue expected to be recognised in FY25 subject to implementation milestones being achieved.

As at 31 December 2024, the total FY25 sold and renewal revenue was $30.8M.

Following the signing of the NCIC and Hywel Dda contracts in February 2025, and subject to meeting implementation milestones, the sold a renewal revenue is currently $39.5M. At this level of revenue, the business is confident it will deliver positive EBTIDA for the full year.

## Significant changes in state of affairs

**Shares on issue and performance rights:**

On 18 September 2024 479,475 performance rights vested for $nil consideration.

On 19 September 2024 2,186,018 performance rights were forfeited.

On 11 November 2024 the Company issued 12,991,977 performance rights to employees in accordance with the Alcidion Group Limited Equity Incentive Plan.

On 20 December 2024 709,939 performance rights were forfeited.

Other than the above, no significant changes in the state of affairs of the Group occurred during the interim period.

## Significant Events after the Balance Date

Subsequent to the period end Alcidion announced that it had signed new material contracts with Hywel Dda University Health Board and North Cumbria Integrated Care. Details of these contracts can be found above in Likely developments and expected results.

Other than the events detailed above, there were no significant events after 31 December 2024.

## Dividends

No dividends were paid or declared during the half year and no recommendation for payment of dividends has been made. (Prior year: $Nil)

## Rounding

The Company is a company of the kind referred to in *ASIC Corporations (Rounding in Financials/Directors' Reports) Instruments 2016/191*, dated 24 March 2016, and in accordance with that Corporations Instrument amounts in this directors' report and financial report are rounded off to the nearest thousand dollars, unless otherwise indicated.

## Auditors Independence Declaration

A copy of the auditor's independence declaration as required under s.307C of the Corporations Act 2001 is set out on page 5.

Signed in accordance with a resolution of directors made pursuant to s.306(3) of the Corporations Act 2001.

On behalf of the Directors

**Rebecca Wilson**
Non-Executive Chair
Melbourne, 27 February 2025

For personal use only

# Auditor's Independence Declaration

For personal use only

William Buck
ACCOUNTANTS & ADVISORS

## Lead Auditor's Independence Declaration under Section 307c of the Corporations Act 2001

### To the Directors of Alcidion Group Limited

As lead auditor for the review of Alcidion Group Limited for the half-year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been:

— no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and

— no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Alcidion Group Limited and the entities it controlled during the period.

William Buck

**William Buck (SA)**
ABN: 38 280 203 274

G Martinella

**G.W. Martinella**
Partner

Dated this 27th day of February, 2025.

Level 6, 211 Victoria Square, Adelaide SA 5000
GPO Box 11050, Adelaide SA 5001
+61 8 8409 4333
sa.info@williambuck.com
williambuck.com

William Buck is an association of firms, each trading under the name of William Buck across Australia and New Zealand with affiliated offices worldwide.
Liability limited by a scheme approved under Professional Standards Legislation.

PRAXITY

# Statement of profit or loss and other comprehensive income

| CONSOLIDATED | Note | 31 Dec 2024 $000 | 31 Dec 2023 $000 |
|---|---|---|---|
| Revenue | | 17,638 | 19,059 |
| Direct costs | | (2,272) | (2,322) |
| **Gross Profit** | | **15,366** | **16,737** |
| Interest income | | 57 | 30 |
| Employee benefits expense | | (12,921) | (16,273) |
| Professional fees | | (628) | (541) |
| Marketing expenses | | (299) | (456) |
| Other expenses | | (1,189) | (2,391) |
| Depreciation and amortisation expense | 3 | (1,453) | (1,632) |
| Finance costs | | (40) | (52) |
| **Loss before income tax expense** | | **(1,107)** | **(4,578)** |
| Income tax benefit / (expense) | | 218 | 242 |
| **Loss after tax attributable to the owners of the Company** | | **(889)** | **(4,336)** |
| **Other comprehensive income/(loss) net of tax** | | | |
| *Items that may be reclassified subsequently to profit or loss:* | | | |
| Exchange differences on translation of foreign operations | | (809) | 178 |
| **Total comprehensive loss for the half year attributable to the owners of the Company** | | **(1,698)** | **(4,158)** |
| **(Loss) Per Share** | | | |
| Basic and diluted loss per share (cents) | 8 | (0.07) | (0.34) |

The notes following the financial statements form part of the financial report.

For personal use only

# Statement of financial position

| CONSOLIDATED | Note | 31 Dec 2024 $000 | 30 June 2024 $000 |
|---|---|---|---|
| **Current assets** | | | |
| Cash and cash equivalents | | 7,681 | 11,798 |
| Trade and other receivables | 4 | 9,759 | 5,214 |
| Other assets | | 1,645 | 1,527 |
| **Total current assets** | | **19,085** | **18,539** |
| | | | |
| **Non-current assets** | | | |
| Plant and equipment | | 256 | 384 |
| Intangible assets | 5 | 93,053 | 93,951 |
| Right of use assets | | 1,347 | 1,586 |
| **Total non-current assets** | | **94,656** | **95,921** |
| **Total assets** | | **113,741** | **114,460** |
| | | | |
| **Liabilities** | | | |
| **Current liabilities** | | | |
| Trade and other payables | | 4,225 | 3,233 |
| Employee provisions | | 2,432 | 2,316 |
| Lease liabilities | | 655 | 697 |
| Income tax payable | | 142 | 134 |
| Unearned revenue | | 13,035 | 12,826 |
| **Total current liabilities** | | **20,489** | **19,206** |
| | | | |
| **Non-current liabilities** | | | |
| Employee provisions | | 132 | 148 |
| Other provisions | | 564 | 443 |
| Deferred tax liabilities | | 6,507 | 6,725 |
| Lease liabilities | | 711 | 998 |
| **Total non-current liabilities** | | **7,914** | **8,314** |
| **Total liabilities** | | **28,403** | **27,520** |
| **Net assets** | | **85,338** | **86,940** |
| | | | |
| **Equity** | | | |
| Issued capital | 6 | 115,515 | 115,515 |
| Share based payment reserves | | 1,190 | 1,094 |
| Foreign currency translation reserve | | (458) | 351 |
| Accumulated losses | | (30,909) | (30,020) |
| **Total equity** | | **85,338** | **86,940** |

The notes following the financial statements form part of the financial report.

For personal use only

# Statement of changes in equity

| CONSOLIDATED | Issued capital | Share based payment reserves | Foreign currency translation reserve | Accumulated losses | Total equity |
|---|---|---|---|---|---|
| | $000 | $000 | $000 | $000 | $000 |
| **Balance as at 1 July 2023** | **110,511** | **942** | **315** | **(21,603)** | **90,165** |
| Loss for the period | - | - | - | (4,336) | (4,336) |
| Other comprehensive income net of tax | - | - | 178 | - | 178 |
| **Total comprehensive income** | **-** | **-** | **178** | **(4,336)** | **(4,158)** |
| *Transactions with owners in their capacity as owners:* | | | | | |
| Share capital issued | 5,012 | - | - | - | 5,012 |
| Share-based payment expense | - | 136 | - | - | 136 |
| **Balance at 31 Dec 2023** | **115,523** | **1,078** | **493** | **(25,939)** | **91,115** |
| | | | | | |
| **Balance as at 1 July 2024** | **115,515** | **1,094** | **351** | **(30,020)** | **86,940** |
| Loss for the period | - | - | - | (889) | (889) |
| Other comprehensive income net of tax | - | - | (809) | - | (809) |
| **Total comprehensive income** | **-** | **-** | **(809)** | **(889)** | **(1,698)** |
| *Transactions with owners in their capacity as owners:* | | | | | |
| Share capital issued | - | - | - | - | - |
| Share-based payment expense | - | 96 | - | - | 96 |
| **Balance at 31 Dec 2024** | **115,515** | **1,190** | **(458)** | **(30,909)** | **85,338** |

The notes following the financial statements form part of the financial report.

For personal use only

# Statement of cash flows

| CONSOLIDATED | Note | 31 Dec 2024 $000 | 31 Dec 2023 $000 |
|---|---|---|---|
| **Cash flows from operating activities** | | | |
| Receipts from customers | | 15,342 | 15,105 |
| Payments to suppliers and employees | | (19,481) | (26,505) |
| Interest received | | 57 | 30 |
| Finance costs | | (40) | (52) |
| **Net cash (outflow) from operating activities** | | **(4,122)** | **(11,422)** |
| | | | |
| **Cash flows from investing activities** | | | |
| Payments for plant and equipment | | (10) | (45) |
| **Net cash (used) for investing activities** | | **(10)** | **(45)** |
| | | | |
| **Cash flows from financing activities** | | | |
| Proceeds from issues of equity securities | | - | 5,403 |
| Transaction costs related to issues of equity securities | | - | (391) |
| Repayment of principal on lease liabilities | | (346) | (328) |
| **Net cash (outflows)/inflows from financing activities** | | **346** | **4,684** |
| | | | |
| Net (decrease) in cash and cash equivalents | | (4,478) | (6,783) |
| Effects of exchange rate changes on cash and cash equivalents | | 361 | 56 |
| Cash and cash equivalents at the beginning of the period | | 11,798 | 14,641 |
| **Cash and cash equivalents at the end of the period** | | **7,681** | **7,914** |

The notes following the financial statements form part of the financial report.

For personal use only

# Notes to the financial statements

## 1. General information

Alcidion Group Limited ("Alcidion" or the "Group" or the "Company") is a limited company incorporated in Australia. The core of Alcidion's business model is to create intellectual property in the form of Clinical Information System software developed to improve the quality of care for all patients and improve the productivity of clinicians and care teams.

The Company's software is bundled with other technologies and services to create complete clinical and business solutions for healthcare providers. Alcidion builds, sells, delivers, hosts and supports solutions for health care provider organisations in Australia, New Zealand and the United Kingdom.

## 2. Material accounting policy information

These consolidated financial statements are general purpose interim financial statements which have been prepared in accordance with the Corporations Act 2001, and Australian Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'

This interim financial report is intended to provide users with an update on the latest annual financial statements of the Group. As such, it does not contain information that represents relatively immaterial changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2024, together with any public announcements made during the half year.

The half-year financial statements were authorised for issue by the directors on 27 February 2025.

### 2.1 Basis of preparation

The financial statements comprise the consolidated financial statements of the Group which comprises the Company and its legal subsidiaries. For the purposes of preparing the consolidated financial statements, the Group is a for-profit entity. Except for the changes disclosed at Note 2.2 below, the same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent financial statements.

The condensed interim financial consolidated financial statements of the Group are for the six months ended 31 December 2024 and are presented in Australian Dollars ($), which is the functional currency of the Parent Company.

### 2.2 New or amended accounting standard and interpretations adopted

The Group has adopted all new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. There has been no impact from this adoption.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been adopted early.

## 3. Depreciation and amortisation

| | 31 Dec 2024 $000 | 31 Dec 2023 $000 |
|---|---|---|
| Depreciation of plant and equipment | 145 | 215 |
| Depreciation of right of use assets | 410 | 416 |
| Amortisation of intangible assets | 898 | 1,001 |
| **Total Depreciation and amortisation** | **1,453** | **1,632** |

For personal use only

For personal use only

## 4. Trade and other receivables

| | 31 Dec 2024 $000 | 30 June 2024 $000 |
|---|---|---|
| Trade receivables | 8,206 | 3,546 |
| Accrued income | 1,553 | 1,668 |
| | **9,759** | **5,214** |

## 5. Intangible assets

| | Goodwill $000 | Customer contracts $000 | Acquired Software $000 | Patents & Trademarks $000 | Total $000 |
|---|---|---|---|---|---|
| **Cost** | | | | | |
| **At 1 July 2023** | **67,763** | **15,595** | **16,399** | **341** | **100,098** |
| Additions | - | - | - | - | - |
| **At 30 June 2024** | **67,763** | **15,595** | **16,399** | **341** | **100,098** |
| **At 1 July 2024** | **67,763** | **15,595** | **16,399** | **341** | **100,098** |
| Additions | - | - | - | - | - |
| **At 31 December 2024** | **67,763** | **15,595** | **16,399** | **341** | **100,098** |
| **Accumulated amortisation** | | | | | |
| **At 1 July 2023** | **-** | **936** | **2,232** | **97** | **3,265** |
| Amortisation expense | **-** | 1,453 | 1,369 | 60 | 2,882 |
| **At 30 June 2024** | **-** | **2,389** | **3,601** | **157** | **6,147** |
| **At 1 July 2024** | **-** | **2,389** | **3,601** | **157** | **6,147** |
| Amortisation expense | - | 187 | 683 | 28 | 898 |
| **At 31 December 2024** | - | **2,576** | **4,284** | **185** | **7,045** |
| **Carrying value** | | | | | |
| At 30 June 2024 | 67,763 | 13,206 | 12,798 | 184 | 93,951 |
| **At 31 December 2024** | **67,763** | **13,019** | **12,115** | **156** | **93,053** |

## 6. Issued capital

| Consolidated | 6 Months to 31 December 2024 | | 12 months to 30 June 2024 | |
|---|---|---|---|---|
| | No. | $000 | No. | $000 |
| Opening balance | 1,342,473,221 | 115,515 | 1,268,069,053 | 110,511 |
| Shares issued during the period: | | | | |
| Performance rights vested | 479,475 | - | 2,364,226 | - |
| Placement/SPP | - | - | 72,039,942 | 5,004 |
| **Closing balance** | **1,342,952,696** | **115,515** | **1,342, 473,221** | **115,515** |

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

## 7. Dividends

There were no dividends paid or proposed during the period. (Prior year: nil)

## 8. Loss per share

| Earnings (loss) per share | 31 Dec 2024 Cents | 31 Dec 2023 Cents |
|---|---|---|
| Basic and diluted earnings (loss) per share | (0.07) | (0.34) |

**(a) Earnings used in calculating basic and diluted earnings per share**

| | 31 Dec 2024 $000 | 31 Dec 2023 $000 |
|---|---|---|
| (Loss) attributable to ordinary shareholders of the Group used in calculating basic and diluted earnings (loss) per share | (889) | (4,366) |

**(b) Weighted average number of shares used as denominator to calculate basic and diluted earnings per share**

| Weighted average number of ordinary shares used in calculating | December 2024 No. | December 2023 No. |
|---|---|---|
| basic & diluted earnings per share | 1,342,744,229 | 1,290,363,574 |

## 9. Commitments

As at 31 December 2024 the Group has no commitments (30 June 2024: nil)

## 10. Contingencies

In the opinion of the Directors, the Group did not have any contingent liabilities or contingent assets as at 31 December 2024 (30 June 2024: nil).

For personal use only

For personal use only

## 11. Segment reporting

The Group operates in the healthcare industry in Australia, New Zealand and the UK. For management purposes, the Group is organised into one main operating segment which involves the provision of healthcare software solutions in all these territories. All the Group's activities are inter-related and financial information is reported to the Board (Chief Operating Decision Maker) as a single segment. All significant operating decisions are based upon analysis of the Group as one segment. The financial results of this segment are therefore equivalent to the financial statements of the Group.

**Basis of accounting for purposes of reporting by operating segments**

**Accounting policies adopted**

Unless stated otherwise, all amounts reported to the Board of Directors, being the chief operating decision makers with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

**Intersegment transactions**

There were no intersegment sales during the period.

**Segment information**

Group Performance - No separate Group performance has been presented in this report as the Board receives only a consolidated Group performance report which is the equivalent to the statement of Profit or Loss and Other Comprehensive Income of the Group as a whole.

Group assets and liabilities - No separate Group asset and liabilities have been presented in this report as the Board only receives a consolidated asset and liabilities report which is the equivalent to the statement of financial position of the Group as a whole.

| Revenue by geographical region | 31 Dec 2024 | | 31 Dec 2023 | |
|---|---|---|---|---|
| | $000 | % | $000 | % |
| Australia / New Zealand | 10,096 | 57% | 11,021 | 58% |
| United Kingdom | 7,542 | 43% | 8,038 | 42% |
| **Total revenue** | **17,638** | | **19,059** | |

| Timing of revenue recognition | 31 Dec 2024 $000 | | | 31 Dec 2023 $000 | | |
|---|---|---|---|---|---|---|
| | Goods transferred at a point in time | Service transferred over time | Total | Goods transferred at a point in time | Service transferred over time | Total |
| Australia / New Zealand | 6,467 | 3,629 | 10,096 | 6,848 | 4,173 | 11,021 |
| United Kingdom | 7,222 | 320 | 7,542 | 7,197 | 841 | 8,038 |
| **Total revenue** | **13,689** | **3,949** | **17,638** | **14,045** | **5,014** | **19,059** |

**Major customers**

During the period the group had one customer that individually accounts for more than 10% of revenue:

- Leidos Australia $4,627K (26.2%) (Dec 23: $5,860K (30.7%))

## 12. Related party disclosures

(a) **Loans to key management personnel and their related parties**

There have been no loans to key management personnel during the current or previous financial year.

(b) **Other transactions with key management personnel**

For the period 1 July 2024 to 30 December 2024 there were no replated party transactions to report.

In the previous half-year period, WE Communications was paid $190,598 for Investor Relations and marketing services, a company in which non-executive director Rebecca Wilson then had an interest but did not financially benefit from.

From 27 February 2024 Ms Wilson was no longer a related party of WE Communications.

Balance payable to related parties as at 31 December 2024 was $Nil (30 June 2024: $Nil).

Transactions between related parties are on normal commercial terms and conditions no more or less favourable than those available to other parties.

## 13. Events after the end of the interim period

Subsequent to the period end Alcidion announced that it had signed two new material contracts in the United Kingdom with Hywel Dda University Health Board and North Cumbria Integrated Care. Details of these contracts can be found in the Directors' report.

Other than the events detailed above no matter or circumstances have arisen since the end of the half-year reporting period which significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future years.

For personal use only

## Directors' declaration

The directors declare that:

a) in the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and

b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the Group for the half year ended 31 December 2024.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the *Corporations Act 2001*.

On behalf of the Directors

**Rebecca Wilson**
Non-Executive Chair
Melbourne, 27 February 2025

For personal use only

# Independent Auditor's Review Report

For personal use only

William Buck
ACCOUNTANTS & ADVISORS

## Independent auditor's review report to the members of Alcidion Group Limited

### Report on the half-year financial report

#### Our conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Alcidion Group Limited (the Company), and its subsidiaries (the Group) does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 31 December 2024 and of its financial performance for the half-year then ended; and
- complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

#### What was reviewed?

We have reviewed the accompanying half-year financial report of the Group, which comprises:

- the consolidated statement of financial position as at 31 December 2024,
- the consolidated statement of profit or loss and other comprehensive income for the half-year then ended,
- the consolidated statement of changes in equity for the half-year then ended,
- the consolidated statement of cash flows for the half-year then ended,
- notes to the financial statements, including a summary of material accounting policy information, and
- the directors' declaration.

### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's responsibilities for the review of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Level 6, 211 Victoria Square, Adelaide SA 5000
GPO Box 11050, Adelaide SA 5001
+61 8 8409 4333
sa.info@williambuck.com
williambuck.com

William Buck is an association of firms, each trading under the name of William Buck across Australia and New Zealand with affiliated offices worldwide.
Liability limited by a scheme approved under Professional Standards Legislation.

PRAXITY

# Independent Auditor's Review Report

For personal use only

## Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

## Auditor's responsibilities for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

William Buck

**William Buck (SA)**
ABN: 38 280 203 274

G Martinella

**G.W. Martinella**
Partner

Dated this 27th day of February, 2025.

# Corporate Directory

**Current Directors (Alcidion Group Limited)**

| Name | Position | Date of Appointment |
|---|---|---|
| Ms Rebecca Wilson | Non-Executive Chair | 01/08/2017 |
| Ms Kate Quirke | Managing Director | 03/07/2018 |
| Ms Victoria Weekes | Non-Executive Director | 01/09/2021 |
| Mr Daniel Sharp | Non-Executive Director | 01/09/2021 |
| Mr Will Smart | Non-Executive Director | 01/10/2024 |
| Mr Michael Sapountzis | Company Secretary | 25/10/2024 |

**Registered office**
Level 4
100 Albert Road
South Melbourne VIC 3205

**Principal place of business**
Level 10
9 Yarra Street
South Yarra VIC 3141
☎ 1800 767 873

**Website**
www.alcidion.com

**Registers of securities**
Computershare Investor Services Pty Ltd
Level 5, 115 Grenfell Street,
Adelaide SA 5000

**Auditors**
William Buck
Level 6, 211 Victoria Square
Adelaide SA 5000

☎ +61 8 8409 4333
🖷 +61 8 8409 4499

DSG
Castle Chambers, 43 Castle Street
Liverpool L2 9TL
England UK

☎ +44 151 294 5400

**Stock Exchange**
Australian Securities Exchange Limited
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

ASX Code: **ALC**

**Tax Accountants**
BDO
Level 11, 1 Margaret St
Sydney, NSW, 2000

☎ +61 2 9251 4100

**Bankers**
Westpac Banking Corporation
Level 30, 275 Kent Street
Sydney, NSW, 2000
☎ 1300 134 291

For personal use only

For personal use only

## ABOUT ALCIDION

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

© Alcidion Group Limited 2025. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

www.alcidion.com
investor@alcidion.com

**Head Office**
Level 10, 9 Yarra Street
SOUTH YARRA VIC 3141
AUSTRALIA
P 1800 767 873